FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2039884403> ?p ?o ?g. }

• W2039884403 endingPage "800" @default.
• W2039884403 startingPage "792" @default.
• W2039884403 abstract "Objective We sought to evaluate efficacy, safety, and tolerability of a combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% (clindamycin-BPO 2.5%) aqueous gel in moderate to severe acne vulgaris. Methods A total of 2813 patients, aged 12 years or older, were randomized to receive clindamycin-BPO 2.5%, individual active ingredients, or vehicle in two identical, double-blind, controlled 12-week, 4-arm studies evaluating safety and efficacy (inflammatory and noninflammatory lesion counts) using Evaluator Global Severity Score and subject self-assessment. Results Clindamycin-BPO 2.5% demonstrated statistical superiority to individual active ingredients and vehicle in reducing both inflammatory and noninflammatory lesions and acne severity. Visibly greater improvement was observed by patients with clindamycin-BPO 2.5% as early as week 2. No substantive differences were seen in cutaneous tolerability among treatment groups and less than 1% of patients discontinued treatment because of adverse events. Limitations Data from controlled studies may differ from clinical practice. Conclusions Clindamycin-BPO 2.5% provides statistically significant greater efficacy than individual active ingredients and vehicle with a highly favorable safety and tolerability profile. We sought to evaluate efficacy, safety, and tolerability of a combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% (clindamycin-BPO 2.5%) aqueous gel in moderate to severe acne vulgaris. A total of 2813 patients, aged 12 years or older, were randomized to receive clindamycin-BPO 2.5%, individual active ingredients, or vehicle in two identical, double-blind, controlled 12-week, 4-arm studies evaluating safety and efficacy (inflammatory and noninflammatory lesion counts) using Evaluator Global Severity Score and subject self-assessment. Clindamycin-BPO 2.5% demonstrated statistical superiority to individual active ingredients and vehicle in reducing both inflammatory and noninflammatory lesions and acne severity. Visibly greater improvement was observed by patients with clindamycin-BPO 2.5% as early as week 2. No substantive differences were seen in cutaneous tolerability among treatment groups and less than 1% of patients discontinued treatment because of adverse events. Data from controlled studies may differ from clinical practice. Clindamycin-BPO 2.5% provides statistically significant greater efficacy than individual active ingredients and vehicle with a highly favorable safety and tolerability profile." @default.
• W2039884403 created "2016-06-24" @default.
• W2039884403 creator A5008772023 @default.
• W2039884403 creator A5039370336 @default.
• W2039884403 creator A5040030393 @default.
• W2039884403 creator A5056006572 @default.
• W2039884403 creator A5064431060 @default.
• W2039884403 creator A5075725987 @default.
• W2039884403 date "2008-11-01" @default.
• W2039884403 modified "2023-10-03" @default.
• W2039884403 title "An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: Assessment of efficacy and safety in 2813 patients" @default.
• W2039884403 cites W1480797756 @default.
• W2039884403 cites W1965109760 @default.
• W2039884403 cites W1965659086 @default.
• W2039884403 cites W1969502034 @default.
• W2039884403 cites W2022880272 @default.
• W2039884403 cites W2034637695 @default.
• W2039884403 cites W2065888108 @default.
• W2039884403 cites W2094108958 @default.
• W2039884403 cites W2098409968 @default.
• W2039884403 cites W2164422954 @default.
• W2039884403 cites W2238949020 @default.
• W2039884403 doi "https://doi.org/10.1016/j.jaad.2008.06.040" @default.
• W2039884403 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18805603" @default.
• W2039884403 hasPublicationYear "2008" @default.
• W2039884403 type Work @default.
• W2039884403 sameAs 2039884403 @default.
• W2039884403 citedByCount "91" @default.
• W2039884403 countsByYear W20398844032012 @default.
• W2039884403 countsByYear W20398844032013 @default.
• W2039884403 countsByYear W20398844032014 @default.
• W2039884403 countsByYear W20398844032015 @default.
• W2039884403 countsByYear W20398844032016 @default.
• W2039884403 countsByYear W20398844032017 @default.
• W2039884403 countsByYear W20398844032018 @default.
• W2039884403 countsByYear W20398844032019 @default.
• W2039884403 countsByYear W20398844032020 @default.
• W2039884403 countsByYear W20398844032021 @default.
• W2039884403 countsByYear W20398844032022 @default.
• W2039884403 countsByYear W20398844032023 @default.
• W2039884403 crossrefType "journal-article" @default.
• W2039884403 hasAuthorship W2039884403A5008772023 @default.
• W2039884403 hasAuthorship W2039884403A5039370336 @default.
• W2039884403 hasAuthorship W2039884403A5040030393 @default.
• W2039884403 hasAuthorship W2039884403A5056006572 @default.
• W2039884403 hasAuthorship W2039884403A5064431060 @default.
• W2039884403 hasAuthorship W2039884403A5075725987 @default.
• W2039884403 hasConcept C126322002 @default.
• W2039884403 hasConcept C16005928 @default.
• W2039884403 hasConcept C168563851 @default.
• W2039884403 hasConcept C178790620 @default.
• W2039884403 hasConcept C185592680 @default.
• W2039884403 hasConcept C197934379 @default.
• W2039884403 hasConcept C2777458120 @default.
• W2039884403 hasConcept C2777673923 @default.
• W2039884403 hasConcept C2778375690 @default.
• W2039884403 hasConcept C2778885487 @default.
• W2039884403 hasConcept C44228677 @default.
• W2039884403 hasConcept C501593827 @default.
• W2039884403 hasConcept C521977710 @default.
• W2039884403 hasConcept C55493867 @default.
• W2039884403 hasConcept C71924100 @default.
• W2039884403 hasConceptScore W2039884403C126322002 @default.
• W2039884403 hasConceptScore W2039884403C16005928 @default.
• W2039884403 hasConceptScore W2039884403C168563851 @default.
• W2039884403 hasConceptScore W2039884403C178790620 @default.
• W2039884403 hasConceptScore W2039884403C185592680 @default.
• W2039884403 hasConceptScore W2039884403C197934379 @default.
• W2039884403 hasConceptScore W2039884403C2777458120 @default.
• W2039884403 hasConceptScore W2039884403C2777673923 @default.
• W2039884403 hasConceptScore W2039884403C2778375690 @default.
• W2039884403 hasConceptScore W2039884403C2778885487 @default.
• W2039884403 hasConceptScore W2039884403C44228677 @default.
• W2039884403 hasConceptScore W2039884403C501593827 @default.
• W2039884403 hasConceptScore W2039884403C521977710 @default.
• W2039884403 hasConceptScore W2039884403C55493867 @default.
• W2039884403 hasConceptScore W2039884403C71924100 @default.
• W2039884403 hasIssue "5" @default.
• W2039884403 hasLocation W20398844031 @default.
• W2039884403 hasLocation W20398844032 @default.
• W2039884403 hasOpenAccess W2039884403 @default.
• W2039884403 hasPrimaryLocation W20398844031 @default.
• W2039884403 hasRelatedWork W1730169 @default.
• W2039884403 hasRelatedWork W2103367276 @default.
• W2039884403 hasRelatedWork W2373888137 @default.
• W2039884403 hasRelatedWork W2400509156 @default.
• W2039884403 hasRelatedWork W2411059349 @default.
• W2039884403 hasRelatedWork W2415970565 @default.
• W2039884403 hasRelatedWork W245890128 @default.
• W2039884403 hasRelatedWork W2472503628 @default.
• W2039884403 hasRelatedWork W2521324618 @default.
• W2039884403 hasRelatedWork W4210853480 @default.
• W2039884403 hasVolume "59" @default.
• W2039884403 isParatext "false" @default.
• W2039884403 isRetracted "false" @default.
• W2039884403 magId "2039884403" @default.
• W2039884403 workType "article" @default.